JP5501245B2 - Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用 - Google Patents

Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用 Download PDF

Info

Publication number
JP5501245B2
JP5501245B2 JP2010536523A JP2010536523A JP5501245B2 JP 5501245 B2 JP5501245 B2 JP 5501245B2 JP 2010536523 A JP2010536523 A JP 2010536523A JP 2010536523 A JP2010536523 A JP 2010536523A JP 5501245 B2 JP5501245 B2 JP 5501245B2
Authority
JP
Japan
Prior art keywords
peptide
peptides
fviii
factor viii
hemophilia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010536523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505414A5 (enExample
JP2011505414A (ja
Inventor
デイビッド レイス，
Original Assignee
アピトープ インターナショナル エヌブイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アピトープ インターナショナル エヌブイ filed Critical アピトープ インターナショナル エヌブイ
Publication of JP2011505414A publication Critical patent/JP2011505414A/ja
Publication of JP2011505414A5 publication Critical patent/JP2011505414A5/ja
Application granted granted Critical
Publication of JP5501245B2 publication Critical patent/JP5501245B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010536523A 2007-12-04 2008-12-03 Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用 Expired - Fee Related JP5501245B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0723712.6 2007-12-04
GBGB0723712.6A GB0723712D0 (en) 2007-12-04 2007-12-04 Peptides
PCT/GB2008/003996 WO2009071886A1 (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014023217A Division JP6063402B2 (ja) 2007-12-04 2014-02-10 Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用

Publications (3)

Publication Number Publication Date
JP2011505414A JP2011505414A (ja) 2011-02-24
JP2011505414A5 JP2011505414A5 (enExample) 2012-10-25
JP5501245B2 true JP5501245B2 (ja) 2014-05-21

Family

ID=38982965

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010536523A Expired - Fee Related JP5501245B2 (ja) 2007-12-04 2008-12-03 Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用
JP2014023217A Expired - Fee Related JP6063402B2 (ja) 2007-12-04 2014-02-10 Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014023217A Expired - Fee Related JP6063402B2 (ja) 2007-12-04 2014-02-10 Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用

Country Status (25)

Country Link
US (1) US8445448B2 (enExample)
EP (1) EP2227488B3 (enExample)
JP (2) JP5501245B2 (enExample)
KR (1) KR101519840B1 (enExample)
CN (2) CN103709234B (enExample)
AU (1) AU2008332968B2 (enExample)
BR (1) BRPI0820143A2 (enExample)
CA (2) CA2707559C (enExample)
CY (1) CY1115168T1 (enExample)
DK (1) DK2227488T6 (enExample)
EA (1) EA019370B1 (enExample)
EC (1) ECSP10010327A (enExample)
ES (1) ES2458315T7 (enExample)
GB (1) GB0723712D0 (enExample)
HR (1) HRP20140344T4 (enExample)
IL (1) IL205780A (enExample)
MX (1) MX2010006084A (enExample)
MY (1) MY150995A (enExample)
NZ (1) NZ585217A (enExample)
PL (1) PL2227488T6 (enExample)
PT (1) PT2227488E (enExample)
SI (1) SI2227488T1 (enExample)
UA (1) UA101003C2 (enExample)
WO (1) WO2009071886A1 (enExample)
ZA (1) ZA201002997B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030062321A (ko) 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
US8329871B2 (en) * 2008-06-24 2012-12-11 Octapharma Ag Process of purifying coagulation factor VIII
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
US20120135917A1 (en) * 2009-06-16 2012-05-31 Eisaku Yoshihara Anti-Gram Negative Bacteria Agent
PL3260132T3 (pl) * 2010-10-27 2022-08-08 Takeda Pharmaceutical Company Limited Peptydy fviii do wywoływania tolerancji immunologicznej oraz immunodiagnostyki
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
CN104903347B (zh) * 2012-11-12 2020-02-21 艾匹托普国际股份有限公司 肽
GB201314052D0 (en) 2013-08-06 2013-09-18 Apitope Int Nv Peptides
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
US12077607B2 (en) * 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015615A1 (en) * 1989-06-20 1990-12-27 Scripps Clinic And Research Foundation The phospholipid binding domain of factor viii
US6132729A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment
KR20030062321A (ko) 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
US20040096456A1 (en) * 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
PL362324A1 (en) * 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
AU2002312660A1 (en) * 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
MXPA04010061A (es) * 2002-04-18 2004-12-13 Merck Patent Gmbh Factor viii modificado.
CN102816241B (zh) * 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
WO2006003183A1 (de) 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
IL229645A0 (en) * 2013-11-26 2014-03-31 Omrix Biopharmaceuticals Ltd A dry bandage containing thrombin and pectin

Also Published As

Publication number Publication date
BRPI0820143A2 (pt) 2015-05-12
ZA201002997B (en) 2011-07-27
CN101889024B (zh) 2014-04-23
JP6063402B2 (ja) 2017-01-18
JP2014088440A (ja) 2014-05-15
NZ585217A (en) 2012-11-30
CA3005013C (en) 2021-11-16
CA2707559C (en) 2018-07-03
GB0723712D0 (en) 2008-01-16
UA101003C2 (uk) 2013-02-25
PL2227488T3 (pl) 2014-07-31
ES2458315T3 (es) 2014-04-30
ECSP10010327A (es) 2010-09-30
SI2227488T1 (sl) 2014-06-30
CN103709234B (zh) 2017-01-18
AU2008332968B2 (en) 2014-03-20
EA201070681A1 (ru) 2010-10-29
IL205780A0 (en) 2010-11-30
EP2227488B1 (en) 2014-01-22
CA3005013A1 (en) 2009-06-11
PL2227488T6 (pl) 2015-04-30
MX2010006084A (es) 2010-06-23
MY150995A (en) 2014-03-31
HRP20140344T1 (en) 2014-05-09
KR20100087346A (ko) 2010-08-04
CY1115168T1 (el) 2016-12-14
CN101889024A (zh) 2010-11-17
HK1144292A1 (en) 2011-02-11
ES2458315T7 (es) 2015-02-18
JP2011505414A (ja) 2011-02-24
KR101519840B1 (ko) 2015-05-18
EP2227488A1 (en) 2010-09-15
PT2227488E (pt) 2014-04-21
AU2008332968A1 (en) 2009-06-11
CN103709234A (zh) 2014-04-09
DK2227488T6 (en) 2015-02-16
HRP20140344T4 (hr) 2015-07-31
WO2009071886A1 (en) 2009-06-11
US8445448B2 (en) 2013-05-21
EA019370B1 (ru) 2014-03-31
EP2227488B3 (en) 2014-11-19
IL205780A (en) 2015-06-30
US20100323966A1 (en) 2010-12-23
CA2707559A1 (en) 2009-06-11
DK2227488T3 (da) 2014-04-22

Similar Documents

Publication Publication Date Title
JP6063402B2 (ja) Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用
JP5784009B2 (ja) Ｆｖｉｉｉ由来ペプチド
KR102165486B1 (ko) 펩타이드
AU2014200237B2 (en) FVIII peptides and their use in tolerising haemophiliacs
HK1172240A (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1172240B (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1173358B (en) Fviii-derived peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120831

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130918

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140210

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140311

R150 Certificate of patent or registration of utility model

Ref document number: 5501245

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees